Sunitinib Dose Escalation in Metastatic Renal Cell Carcinoma
Background and objective: Sunitinib has been a standard treatment for patients with metastatic renal cell carcinoma (mRCC) since 2006. However, almost all patients will eventually progress. Besides well described mechanisms of primary or secondary resistance, insufficient drug exposure may lead to d...
Bewaard in:
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
SAGE Publishing
2019-08-01
|
| Reeks: | Kidney Cancer |
| Online toegang: | https://doi.org/10.3233/KCA-190055 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|